Merck

Please note that this Web site cannot replace regular discussions with your doctor or health care provider. This site is intended only for residents of the United States, its territories, and Puerto Rico.

Maxalt, Maxalt-MLT
Facts, Triggers, Stages, Symptoms

Stages of a Migraine Attack

Before, during, and after migraine.

Preheadache

Many migraine sufferers experience preheadache (prodrome) as an early warning sign hours or days before migraine. Symptoms of preheadache can include:

Aura

Usually following the preheadache phase, aura is a temporary disturbance of brain function. It's most commonly visual, but can also occur in other ways. Auras can be:

Headache

Usually the most disabling aspect of migraine. The pain is often so intense that it's difficult to comprehend by those who haven't experienced it. Headache can last from a couple of hours to several days. Symptoms of headache can include:

Postheadache

Postheadache (postdrome) begins when the headache pain recedes. It can last hours, or even days, often leaving sufferers feeling "woozy" or "drained." Although this is sometimes attributed to migraine medication, it may actually be due to the migraine itself. Symptoms of postheadache can include:

Watch a video to learn more about the early stages of migraine.

MAXALT is a prescription medicine for the treatment of migraine attacks in adults. Only your health care professional can determine if MAXALT is right for you.

Important Safety Information

Phenylketonurics: MAXALT-MLT contains phenylalanine. Please read the Patient Product Information (PDF: 43KB, 6 pages).

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

Please read the Patient Product Information (PDF: 43KB, 6 pages) and discuss it with your doctor. The physician Prescribing Information (PDF: 112KB, 14 pages) is also listed.

Having trouble paying for your Merck medicine? Merck may be able to help. Visit www.merck.com/merckhelps.

For general health information
Merck Source

MIGR-1005002-0000 07/11